

Rasburicase Dosing Criteria

March 2015

1. Flat dosing: Adult patients receive a maximum of rasburicase 6 mg IV X 1 dose

2. Rasburicase criteria for use:

To receive a dose of rasburicase, patients should have one of the following criteria:

- Established diagnosis of malignancy associated with a high risk of tumor lysis syndrome (TLS) such as:
 - Acute leukemias with WBC > 50,000
 - Burkitt's or lymphoblastic lymphoma
 - Other lymphomas with bulky disease

OR two of the following:

- Hematologic malignancy which may be associated with TLS but not listed above
- Solid tumors with high proliferative rates and rapid response to therapy (germ cell tumor, small cell lung cancer, etc.)
- Uric acid > 7.5 mg/dL
- Signs of renal dysfunction in patients with a malignancy diagnosis
 - SCr >1.5 X ULN (1.875) or oliguria
 - Patients that are scheduled to receive dialysis should not be considered

3. Patients may receive an additional dose of rasburicase 6 mg IV X 1 within 7 days if the uric acid >2.5 mg/dL.

4. Laboratory: Uric acid levels obtained for 4 days after a dose of rasburicase will be ordered under a separate orderable from traditional uric acid.